Serum MIF in Acute Kidney Injury

Completed

• Conditions: Acute Kidney Injury
• Interventions: Other: Blood draw for measurement of MIF

• Registration Number: NCT02352506
• Lead Sponsor: Medical University of Vienna

Brief Summary

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-01-28
• Study First Submitted QC: 2015-01-28
• Study First Posted: 2015-02-02
• Primary Completion: 2019-11
• Study Completion: 2023-01
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-13
• Last Update Posted: 2023-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

• Age < 18 years and > 80 years
• Patients with chronic dialysis
• Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
• Patients with an expected length of ICU stay shorter than 3 days
• Patients with a low probability of surviving the first 2 days after ICU admission
• Pregnancy and nursing

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
No AKI	Blood draw for measurement of MIF	Matched controls not developing AKI during the ICU stay
AKI	Blood draw for measurement of MIF	Patients developing AKI during the ICU stay

Primary Outcome Measures

Name	Time	Method
Macrophage migration inhibitory factor	Up to 14 days

Secondary Outcome Measures

Name	Time	Method
Serum creatinine	Up to 14 days

Trial Locations

Locations (1)

Medical University of Vienna; 🇦🇹 Vienna, Austria